BIOGEN INC (IDP.DE) Stock Fundamental Analysis
Europe - FRA:IDP - US09062X1037 - Common Stock
133 EUR
-1.45 (-1.08%)
Taking everything into account, IDP scores 5 out of 10 in our fundamental rating. IDP was compared to 76 industry peers in the Biotechnology industry. IDP gets an excellent profitability rating and is at the same time showing great financial health properties. IDP has a bad growth rate and is valued cheaply. These ratings could make IDP a good candidate for value investing.
1. Profitability
1.1 Basic Checks
IDP had positive earnings in the past year.
IDP had a positive operating cash flow in the past year.
In the past 5 years IDP has always been profitable.
In the past 5 years IDP always reported a positive cash flow from operatings.
1.2 Ratios
Looking at the Return On Assets, with a value of 5.40%, IDP belongs to the top of the industry, outperforming 82.89% of the companies in the same industry.
Looking at the Return On Equity, with a value of 8.68%, IDP belongs to the top of the industry, outperforming 84.21% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 9.52%, IDP belongs to the top of the industry, outperforming 88.16% of the companies in the same industry.
IDP had an Average Return On Invested Capital over the past 3 years of 10.57%. This is below the industry average of 12.82%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.4% | ||
| ROE | 8.68% | ||
| ROIC | 9.52% |
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.41%
ROIC(3y)10.57%
ROIC(5y)13.65%
1.3 Margins
Looking at the Profit Margin, with a value of 15.31%, IDP belongs to the top of the industry, outperforming 85.53% of the companies in the same industry.
IDP's Profit Margin has declined in the last couple of years.
Looking at the Operating Margin, with a value of 27.35%, IDP belongs to the top of the industry, outperforming 88.16% of the companies in the same industry.
IDP's Operating Margin has declined in the last couple of years.
IDP's Gross Margin of 75.43% is fine compared to the rest of the industry. IDP outperforms 69.74% of its industry peers.
In the last couple of years the Gross Margin of IDP has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 27.35% | ||
| PM (TTM) | 15.31% | ||
| GM | 75.43% |
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.99%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
2. Health
2.1 Basic Checks
IDP has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
The number of shares outstanding for IDP has been increased compared to 1 year ago.
Compared to 5 years ago, IDP has less shares outstanding
The debt/assets ratio for IDP has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 3.14 indicates that IDP is not in any danger for bankruptcy at the moment.
The Altman-Z score of IDP (3.14) is better than 76.32% of its industry peers.
IDP has a debt to FCF ratio of 3.40. This is a good value and a sign of high solvency as IDP would need 3.40 years to pay back of all of its debts.
With an excellent Debt to FCF ratio value of 3.40, IDP belongs to the best of the industry, outperforming 84.21% of the companies in the same industry.
IDP has a Debt/Equity ratio of 0.36. This is a healthy value indicating a solid balance between debt and equity.
IDP has a Debt to Equity ratio (0.36) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.36 | ||
| Debt/FCF | 3.4 | ||
| Altman-Z | 3.14 |
ROIC/WACC1.17
WACC8.15%
2.3 Liquidity
A Current Ratio of 2.50 indicates that IDP has no problem at all paying its short term obligations.
With a Current ratio value of 2.50, IDP perfoms like the industry average, outperforming 55.26% of the companies in the same industry.
IDP has a Quick Ratio of 1.79. This is a normal value and indicates that IDP is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.79, IDP is in line with its industry, outperforming 47.37% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.5 | ||
| Quick Ratio | 1.79 |
3. Growth
3.1 Past
IDP shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 2.51%.
The earnings per share for IDP have been decreasing by -13.31% on average. This is quite bad
The Revenue has decreased by -1.62% in the past year.
Measured over the past years, IDP shows a decrease in Revenue. The Revenue has been decreasing by -7.62% on average per year.
EPS 1Y (TTM)2.51%
EPS 3Y-4.95%
EPS 5Y-13.31%
EPS Q2Q%17.89%
Revenue 1Y (TTM)-1.62%
Revenue growth 3Y-4.13%
Revenue growth 5Y-7.62%
Sales Q2Q%2.79%
3.2 Future
IDP is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 1.15% yearly.
Based on estimates for the next years, IDP will show a decrease in Revenue. The Revenue will decrease by -0.44% on average per year.
EPS Next Y-2.25%
EPS Next 2Y-0.87%
EPS Next 3Y0.6%
EPS Next 5Y1.15%
Revenue Next Year0.43%
Revenue Next 2Y-1.77%
Revenue Next 3Y-1.1%
Revenue Next 5Y-0.44%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 9.17, the valuation of IDP can be described as very reasonable.
Compared to the rest of the industry, the Price/Earnings ratio of IDP indicates a rather cheap valuation: IDP is cheaper than 93.42% of the companies listed in the same industry.
IDP's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 25.83.
IDP is valuated reasonably with a Price/Forward Earnings ratio of 9.48.
Based on the Price/Forward Earnings ratio, IDP is valued cheaper than 96.05% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of IDP to the average of the S&P500 Index (32.68), we can say IDP is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.17 | ||
| Fwd PE | 9.48 |
4.2 Price Multiples
IDP's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. IDP is cheaper than 89.47% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, IDP is valued cheaper than 92.11% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 12.18 | ||
| EV/EBITDA | 7.55 |
4.3 Compensation for Growth
The decent profitability rating of IDP may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-0.87%
EPS Next 3Y0.6%
5. Dividend
5.1 Amount
No dividends for IDP!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FRA:IDP (11/7/2025, 7:00:00 PM)
133
-1.45 (-1.08%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners92.49%
Inst Owner ChangeN/A
Ins Owners0.14%
Ins Owner ChangeN/A
Market Cap19.50B
Revenue(TTM)9.68B
Net Income(TTM)1.53B
Analysts73.81
Price Target150.4 (13.08%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)28.1%
Min EPS beat(2)17.28%
Max EPS beat(2)38.92%
EPS beat(4)4
Avg EPS beat(4)15.59%
Min EPS beat(4)0.67%
Max EPS beat(4)38.92%
EPS beat(8)8
Avg EPS beat(8)13.06%
EPS beat(12)12
Avg EPS beat(12)11.49%
EPS beat(16)14
Avg EPS beat(16)10.96%
Revenue beat(2)2
Avg Revenue beat(2)9.15%
Min Revenue beat(2)6.67%
Max Revenue beat(2)11.62%
Revenue beat(4)3
Avg Revenue beat(4)4.43%
Min Revenue beat(4)-0.68%
Max Revenue beat(4)11.62%
Revenue beat(8)5
Avg Revenue beat(8)1.84%
Revenue beat(12)8
Avg Revenue beat(12)1.78%
Revenue beat(16)11
Avg Revenue beat(16)1.73%
PT rev (1m)2.61%
PT rev (3m)-1.62%
EPS NQ rev (1m)1.19%
EPS NQ rev (3m)-1.54%
EPS NY rev (1m)-0.55%
EPS NY rev (3m)5.44%
Revenue NQ rev (1m)0.17%
Revenue NQ rev (3m)2.8%
Revenue NY rev (1m)0.03%
Revenue NY rev (3m)4.49%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.17 | ||
| Fwd PE | 9.48 | ||
| P/S | 2.25 | ||
| P/FCF | 12.18 | ||
| P/OCF | 10.62 | ||
| P/B | 1.28 | ||
| P/tB | 13.44 | ||
| EV/EBITDA | 7.55 |
EPS(TTM)14.51
EY10.91%
EPS(NY)14.03
Fwd EY10.55%
FCF(TTM)10.92
FCFY8.21%
OCF(TTM)12.52
OCFY9.41%
SpS59.12
BVpS104.29
TBVpS9.9
PEG (NY)N/A
PEG (5Y)N/A
Graham Number184.52
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.4% | ||
| ROE | 8.68% | ||
| ROCE | 10.87% | ||
| ROIC | 9.52% | ||
| ROICexc | 10.7% | ||
| ROICexgc | 37.26% | ||
| OM | 27.35% | ||
| PM (TTM) | 15.31% | ||
| GM | 75.43% | ||
| FCFM | 18.47% |
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.41%
ROIC(3y)10.57%
ROIC(5y)13.65%
ROICexc(3y)12.43%
ROICexc(5y)16.11%
ROICexgc(3y)38.35%
ROICexgc(5y)40.12%
ROCE(3y)12.07%
ROCE(5y)15.58%
ROICexgc growth 3Y14.15%
ROICexgc growth 5Y-5.35%
ROICexc growth 3Y-15.93%
ROICexc growth 5Y-20.8%
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.99%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
F-Score6
Asset Turnover0.35
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.36 | ||
| Debt/FCF | 3.4 | ||
| Debt/EBITDA | 1.81 | ||
| Cap/Depr | 36.28% | ||
| Cap/Sales | 2.7% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 60.86% | ||
| Profit Quality | 120.66% | ||
| Current Ratio | 2.5 | ||
| Quick Ratio | 1.79 | ||
| Altman-Z | 3.14 |
F-Score6
WACC8.15%
ROIC/WACC1.17
Cap/Depr(3y)54.43%
Cap/Depr(5y)68.89%
Cap/Sales(3y)3.09%
Cap/Sales(5y)3.21%
Profit Quality(3y)99.34%
Profit Quality(5y)120.98%
High Growth Momentum
Growth
EPS 1Y (TTM)2.51%
EPS 3Y-4.95%
EPS 5Y-13.31%
EPS Q2Q%17.89%
EPS Next Y-2.25%
EPS Next 2Y-0.87%
EPS Next 3Y0.6%
EPS Next 5Y1.15%
Revenue 1Y (TTM)-1.62%
Revenue growth 3Y-4.13%
Revenue growth 5Y-7.62%
Sales Q2Q%2.79%
Revenue Next Year0.43%
Revenue Next 2Y-1.77%
Revenue Next 3Y-1.1%
Revenue Next 5Y-0.44%
EBIT growth 1Y23.31%
EBIT growth 3Y-8.8%
EBIT growth 5Y-18.9%
EBIT Next Year7.73%
EBIT Next 3Y2.84%
EBIT Next 5Y5.8%
FCF growth 1Y64.41%
FCF growth 3Y-9.06%
FCF growth 5Y-17.06%
OCF growth 1Y48.2%
OCF growth 3Y-7.56%
OCF growth 5Y-16.49%
BIOGEN INC / IDP.DE FAQ
What is the ChartMill fundamental rating of BIOGEN INC (IDP.DE) stock?
ChartMill assigns a fundamental rating of 5 / 10 to IDP.DE.
Can you provide the valuation status for BIOGEN INC?
ChartMill assigns a valuation rating of 7 / 10 to BIOGEN INC (IDP.DE). This can be considered as Undervalued.
What is the profitability of IDP stock?
BIOGEN INC (IDP.DE) has a profitability rating of 7 / 10.
Can you provide the financial health for IDP stock?
The financial health rating of BIOGEN INC (IDP.DE) is 7 / 10.
Can you provide the expected EPS growth for IDP stock?
The Earnings per Share (EPS) of BIOGEN INC (IDP.DE) is expected to decline by -2.25% in the next year.